OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) and STENOCARE are into a new progressive deal. The two business giants just moved into a Memorandum of Understanding (MoU) that is quite strategic. These two seek to engage in the development and the commercialization of some wide-ranging cannabis-based medical products.

Terms of the deal

Each of the parties will have something to gain from the deal. For instance, OWC’s technologies will benefit from a more expansive market. On the other hand, the business strategy of STENOCARE might end up becoming a huge success. The business guru has been looking forward to supplementing its top-quality generic medical cannabis products. Its target has been to supplement them with differentiated products meant to treat numerous patient groups struggling with particular serious conditions.

The new cooperation means well for them, considering that they will increase their sales massively. They will also be able to distribute products in large volumes within the existing core markets of STENOCARE. The businesses also want to venture into new territories in their quest to boost their business profits.

STENOCARE and its plans

STENOCARE expresses its willingness to deliver some top quality cannabis raw materials. Asides from that, it will also be seeking to provide extensive knowledge in line with the supply and the distribution of the medical cannabis-based products in Ireland and Denmark as well.

On the other hand, OWC Pharmaceutical says it will offer its expertise in clinical trials and medical research. The business has been focusing on cannabis products providing therapeutic solutions to patients. It prides itself on having in place what it terms an extensive Intellectual Property Portfolio.

The first product candidate

The information regarding the first product candidate for this collaboration is already out. This will be a sublingual tablet pulling along with specified medical cannabis ratios vital in meeting up to the needs of patients. It will be important to make the appropriate diagnosis as well as check out how they will be responding to treatment.

The CEO of OWC Pharmaceutical Research Mordechai Bignitz says that STENOCARE is a great choice for a partner. He says that considering the company’s capacity in the distribution of medical cannabis products to some interesting markets. This official also speaks about the focus on pharma-grade production.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Announces Positive Safety Results From The First Phase Study For Medical Cannabis Ointment For Skin Disease Treatment OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Issues Chairman’s Statement to Shareholders OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Topical Cream In Focus CFN Media Interviews OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) CSO OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) To Commence Safety Testing On Its CBD-Infused Cream

Pin It on Pinterest